- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Bile duct cancer (cholangiocarcinoma)
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 1.6MB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 1.3MB)
Ivosidenib – July 2024
Ivosidenib; Tablet 250 mg; Tibsovo®
Last updated
30 May 2025